Are Antidepressants Safe during Pregnancy & Breastfeeding?

Up to ~25% of pregnant women will suffer from depression while pregnant.1 The decision on how to treat depression and/or anxiety during & after pregnancy requires careful consideration of benefits and harms & collaborative discussions with the patient.

**SHOULD ANTIDEPRESSANTS BE DISCONTINUED BEFORE OR DURING PREGNANCY? 1,2**

- It depends on the patient’s previous and current mental health status.
- Patients may be a candidate for tapering and discontinuing their antidepressant if they have had **mild or no symptoms** for ≥6 months. Taper the dose by ↓ 25% every 1-2 weeks. Work with patient & family to monitor closely for signs of relapse & withdrawal symptoms.
- **Patients should not** discontinue their antidepressant if they have a history of severe recurrent depression, psychosis, bipolar illness, serious suicide attempt, psychiatric comorbidities requiring drug therapy and/or anxiety… even if asymptomatic. In such patients, the harm of not taking an antidepressant may exceed the harm of taking drug therapy.
- **The rate of relapse is high during pregnancy.** Based on a prospective cohort study, females who suffered from recurrent major depression & discontinued their antidepressant during pregnancy were **5 times** more likely to relapse compared to those who maintained their medication.2 Of those who relapsed, ~50% did so during the 1st trimester, with ~90% by the end of the 2nd trimester.

**IS THERE ANY HARM IN NOT TREATING DEPRESSION AND/OR ANXIETY DURING PREGNANCY & POSTPARTUM? 3,4,5,6,7,8,9,10,11**

- Untreated depression and/or anxiety can put the mother & fetus/baby at risk, with suicide & infanticide being the major concern.
- Depressed mothers are more likely to miss prenatal appointments, be malnourished and engage in harmful behaviours (i.e. smoke, drink alcohol and/or use other substances), and are less likely to take prenatal vitamins.
- There is a higher risk of spontaneous abortions, miscarriages, gestational hypertension, preeclampsia, preterm deliveries, low birth weight, small for gestational age, cesarean section, low Apgar scores, need for neonatal intensive care & ↑ length of hospital stay.
  - Some antidepressant studies have found these same risks, but most were unable to control for underlying depression.1
- Postpartum depression can impact the mother’s ability to care for and bond with her child.
- Infants are at a higher risk of irritability, inactivity, inattentiveness, and fewer facial expressions. They often have a similar physiological profile as depressed mothers, such as ↑ cortisol, and ↓ peripheral levels of dopamine, serotonin & norepinephrine. Emotional, emotional and behavioural concerns can surface when an infant is exposed to a chronically depressed mother.

**WHAT IS THE ROLE FOR NON-PHARMACOLOGICAL THERAPIES DURING PREGNANCY & POSTPARTUM PERIOD? 4,6,7**

- Depression and/or anxiety focused psychotherapy (i.e. interpersonal psychotherapy or cognitive behavioural therapy [CBT]) may be considered first line therapy in mild to moderate depression/anxiety. It may also be combined with antidepressants in moderate to severe depression/anxiety in an effort to ↓ the medication dose. **On-line CBT** Saskatchewan residents: **www.onlinetherapyuser.ca** (see on-line Extras).
- **Electroconvulsive therapy (ECT)** is considered safe & effective for depression during pregnancy. It is an option for moderate to severe depression in pregnant patients who are unsuitable for or unresponsive to antidepressants, have psychotic features, &/or are suicidal.
- Exercise & relaxation techniques are recommended for mild depression/anxiety or as an adjuvant for moderate to severe symptoms.

**WHEN SHOULD ANTIDEPRESSANTS BE CONSIDERED? 1,3,4**

- Antidepressants can be used for moderate to severe depression and/or anxiety, ± psychotherapy.
- Although antidepressants are not 1st line in mild depression/anxiety, medication may be tried if psychotherapy is not available or has previously failed, or with a history of severe depression/anxiety or good response to previous antidepressants.

**WHICH ANTIDEPRESSANTS ARE CONSIDERED THE SAFEST DURING PREGNANCY? 1,3,4,6,12,13,14**

- Antidepressants do not appear to significantly ↑ the risk of congenital malformations more than the general population risk of 2-4%.
- Overall, **selective serotonin reuptake inhibitors (SSRIs)** have the most data for reasonable safety during pregnancy. See below for specific concerns with paroxetine; all other SSRIs (e.g. sertraline, citalopram) appear to have a similar safety profile.
- Tricyclic antidepressants (TCAs) do not appear to be teratogenic & serum levels can be monitored; however, anticholinergic side effects & risk of overdose need to be considered. Desipramine, amitriptyline & nortriptyline are the preferred TCAs during pregnancy.
- Newer antidepressants (bupropion, duloxetine, venlafaxine, mirtazapine): these agents do not appear to be teratogenic, but there is limited data available. Bupropion is considered to carry low risk in humans, & may be useful if encouraging smoking cessation.

**DOES PAROXETINE CAUSE CONGENITAL MALFORMATIONS WHEN USED IN THE FIRST TRIMESTER? 1,2,4,6,8,15**

- Accumulated evidence would suggest there is not an increased risk, although some data is conflicting and there are study limitations.
- Case-control, cohort, and meta-analysis of these studies, have not been consistent with their findings. In the studies that found an increased risk of malformations (congenital and/or cardiac) with paroxetine use, the risk was 2-fold or less.
- One study suggested the risk of congenital & cardiac malformations is dose-dependent, with doses >25mg/day.
- If starting an antidepressant in a woman of childbearing potential or who is pregnant – consider selecting an antidepressant other than paroxetine, unless the patient has responded to paroxetine in the past &/or has failed other agents.
- If a pregnant woman is stabilized on paroxetine – you may continue paroxetine, especially if the patient has previously failed other antidepressants. Decreasing the dose may help reduce potential risks. Switching to another antidepressant in the first trimester is an option, but switching medications may result in relapse.
DO SSRIs CAUSE PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN? 1,3,8,16,17,18

- The available data is conflicting and has several limitations. If a true association exists, the risk is very small.
- Persistent pulmonary hypertension of the newborn (PPHN) is a rare but serious complication. There are several causes, including meconium aspiration 40% of cases, smoking, obesity, cesarean section, and preterm delivery, to name a few.
  - Depression itself has been linked to increased risk of cesarean section and preterm delivery.
  - It has been questioned if PPHN and antidepressant neonatal behavioural syndrome are linked, but this has yet to be confirmed.
- PPHN has not been linked to non-SSRI antidepressants.
- Six published studies have investigated the potential link between SSRI use during pregnancy and PPHN. Three studies found no association and the remaining three found a 2.4 to 6-fold increase in risk.
- Limitations of the evidence: studies to date have been case-control or cohort; two of the trials found that an increased risk used the same database, although the more recent study included additional patients; the severity of PPHN and clinical course were not defined, diagnostic criteria varied and not all confounders were accounted for.
- If there is a 2.4 to 6-fold increase of PPHN in infants exposed to SSRIs, the absolute risk increases the baseline risk of 1-2 per 1000 (0.1-0.2%) to 2.4-12 per 1000 (0.3-1.2%). There have been no published reports of SSRI induced PPHN resulting in death.

DO ANTIDEPRESSANTS CAUSE NEONATAL BEHAVIOURAL SYNDROME? 1,3,4,7,8,10,19 a.k.a. neonatal adaptation syndrome

- Neonatal behavioural syndrome has been reported in up to 30% of infants exposed to antidepressants near term however it is felt to be clinically observed in 1/2 of the cases. All antidepressants carry this risk; however, it is usually mild and transient.
- Signs and symptoms include tachypnea, cyanosis, jitteriness, tremors, increased muscle tone, feeding disturbances, irritability, temperature instability, hypoglycemia, and, rarely, seizures.
- Usually presents within hours of birth, is mild and often resolves within two weeks.
- It is not known if it results from neonatal withdrawal or toxicity. In utero nicotine exposure can cause similar symptoms.
- Babies exposed to SSRIs near term should be monitored in hospital for at least 48 hours after delivery. Families should be counseled to observe for the above signs & symptoms.

WHICH ANTIDEPRESSANTS ARE CONSIDERED SAFE DURING BREASTFEEDING? 3,6,9,20,21

- SSRIs have the most safety data during lactation, and are considered to have a better safety profile than TCAs. However, the safety of long-term antidepressant exposure in the infant via breast milk is unknown.
- All SSRIs are excreted into breast milk to varying degrees:
  - Sertraline, paroxetine and fluvoxamine have the lowest degree of excretion into breast milk.
  - Citalopram, escitalopram and fluoxetine have longer half-lives, higher infant doses & greater number of reported infant adverse events.
- The Canadian Pediatric Society recommends that postpartum use of any SSRIs is not a contraindication to breastfeeding.
- Educate mothers to monitor for & report sedation, nausea, reduced suckling or any other sign of drug toxicity in the infant.
- TCAs: amitriptyline, clomipramine, desipramine, imipramine & nortriptyline are likely safe during breastfeeding.
- Newer antidepressants: limited data to support safety during lactation.

DEPRESSION SCREENING CONSIDERATIONS: 6,7,8,22

- When should females be screened for peri-pregnancy depression?
  - Pre-conception: ask about personal and family history of mental health disorders and treatment.
  - Pregnancy: during the first routine antenatal visit.
  - Postpartum: during routine postnatal visits at 4-6 weeks and 3-4 months postpartum.
  - Anytime throughout the antenatal & postnatal period if you are concerned about the female’s mental health.
- Which depression screening tools should be used in pregnancy & postpartum?
  - Edinburgh Postnatal Depression Scale – validated for use during both pregnancy and postpartum
  - Patient Health Questionnaire 9 (PHQ-9)
  - National Institute for Health and Clinical Excellence: Screening for Depression During Pregnancy
- Screening tools do not confirm a diagnosis of depression, but rather identify patients who require further assessment.
- Avoid using screening tools which focus on somatic symptoms (e.g. Beck Depression Inventory) as it can be difficult to distinguish between symptoms of depression versus pregnancy.

WHAT ARE OTHER IMPORTANT CONSIDERATIONS IN THE MANAGEMENT OF DEPRESSION & ANXIETY DURING PREGNANCY? 1,3,4

- Antidepressants may be metabolized more quickly in the 3rd trimester. Increase the dose if needed, but use the lowest dose possible and readjust the dose postpartum dose as needed or required.
- Manage postpartum depression as you would depression during pregnancy.
- Monotherapy is preferred over combination therapy.
- Counsel patients on the risks of stopping antidepressants/anxiolytics abruptly.
- Avoid regular benzodiazepine use for anxiety. 1st trimester use linked to oral cleft malformations. 3rd trimester use linked to “floppy baby” syndrome (hypotonia, lethargy, sucking difficulties) & withdrawal syndrome (tremors, irritability, hypertonicity, diarrhea, vomiting, vigorous sucking).
RxFiles Q&A Are Antidepressants Safe during Pregnancy & Lactation Extras:

ON-LINE COGNITIVE BEHAVIOURAL THERAPY FOR SASKATCHEWAN RESIDENTS (www.onlinetherapyuser.ca):

Saskatchewan females suffering from depression and/or anxiety during and/or after pregnancy may be eligible for on-line cognitive behavioural therapy through the University of Regina (www.onlinetherapyuser.ca). A new specialized service, Maternal Depression Online, is also available for women who have given birth within the last year and who suffer from minor and major depression. The programs are based on cognitive behaviour therapy and include interactive modules that are accessed online. In addition, therapist-assistance is offered with clients receiving support and encouragement from an online therapist through the website on a weekly basis over the course of the program. The programs are currently provided to Saskatchewan women at no cost and are offered through the Online Therapy Unit at the University of Regina which externally funded by the Canadian Institute of Health Research. Maternal Depression Online is being researched by a PhD student in clinical psychology. To better understand the effectiveness of this service, clients are asked to complete questionnaires before and after they finish their program. For more information about online therapy, or to schedule a screening interview, please access www.onlinetherapyuser.ca or contact Nicole Pugh at pugh200n@uregina.ca or (306) 585-5369.

SUMMARY OF KEY POINTS:

- Do consider the potential harm to mother and baby if depression is not treated.
- Do consider cognitive behavioural therapy and interpersonal psychotherapy for mild to moderate depression.
- Do consider using an antidepressant of choice (e.g. SSRI) for patients with a history of moderate to severe depression.
- Don’t forget that the rate of relapse is high in females with recurrent depression who stop their antidepressant during pregnancy.

Acknowledgements: Contributors & Reviewers: Marilyn Baetz MD, FRCP(C), Psychiatry, U of S/SSH, Saskatoon, Alfred Remillard BSc(Pharm), PharmD, BCPS(College of Pharmacy and Nutrition, U of S, Saskatoon), Melanie McLeod BSc, PharmD (RQHR, Regina) and the RxFiles Advisory Committee. Prepared by: L. Kosar, MSPH, L. Regier, BA, B. Jensen, BA

DISCLAIMER: The content of this newsletter represents the views, experience and opinions of the authors and not those of the board or administration of Saskatchewan Health Region (SHR). Neither the authors nor Saskatchewan Health Region nor any other party who has been involved in the preparation or publication of this material assumes any responsibility for the information contained herein or assumes responsibility for any errors or omissions for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgement of this disclaimer. This newsletter contains with other sources. Additional information and references online at www.RxFiles.ca

Copyright 2012 – RxFiles, Saskatoon Health Region (SHR) www.RxFiles.ca

References: